4 results about "Oxoquinolines" patented technology

This invention belongs to the technical field of bactericide residue analysis and determination in plant-derived foods, specifically relating to a method for detecting isobutylethoxyquinoline and its metabolites in plant-derived foods. The method includes extraction with acetonitrile under citrate conditions, followed by purification with C18 (25 mg), PAX (25 mg), and XFM64 (nitrogen-doped multi-walled carbon nanotubes, 10 mg) adsorbents. Chromatographic separation is performed using a C18 column with methanol-2 mmol / L ammonium acetate (containing 0.1% formic acid) as the mobile phase, isocratic elution at a flow rate of 0.40 mL / min, electrospray ionization (ESI+), and detection in multiple reaction monitoring (MRM) mode. This invention is simple to operate, has high pretreatment efficiency, and its precision and recovery rate meet the regulatory residue limit monitoring requirements. It is suitable for the simultaneous determination of isobutylethoxyquinoline and its metabolites in plant-derived foods.

The invention relates to the technical field of pharmaceutical analysis, and particularly discloses a method for detecting related substances of 2-amino-3-(1, 2-dihydro-2-oxoquinoline-4-yl) propionic acid hydrochloride. The detection method provided by the invention can be used for rapidly detecting related substances of the 2-amino-3-(1, 2-dihydro-2-quinoline-4-yl) propionic acid hydrochloride, is high in precision, accuracy and sensitivity and good in reproducibility and stability, can be used for quality control and comprehensive evaluation of the 2-amino-3-(1, 2-dihydro-2-quinoline-4-yl) propionic acid hydrochloride, and has a wide application prospect. A reliable guarantee is provided for improving and controlling the quality of the 2-amino-3-(1, 2-dihydro-2-oxoquinoline-4-yl) propionic acid hydrochloride.

The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.